Reduce Parkinson progression with antiinflammatory
- Trial ID
- NCT07370532
- Official Title
- Clinical Study to Evaluate Safety and Efficacy of Etoricoxib in Patients With Parkinson's Disease Treated With Conventional Treatment
- Goal
- Reduce Parkinson progression with antiinflammatory
- Phase
- PHASE2
- Status
- RECRUITING
- Sponsor
- Ihab Elsayed Hassan
- Study Type
- INTERVENTIONAL
- Enrollment
- 60 participants
- Conditions
- Parkinson Disease
- Interventions
- L-dopa, Etoricoxib
Plain-Language Summary
Researchers are testing whether adding etoricoxib, a selective COX-2 anti-inflammatory, to usual levodopa care is safe and may help by reducing the inflammation that might contribute to neuron damage and symptom worsening in Parkinson's. Etoricoxib works by blocking the COX-2 enzyme and lowering prostaglandin-driven inflammation; it does not boost dopamine like levodopa, but by reducing inflammatory stress it could protect neurons or slow decline, and the study will watch for safety and interactions with standard Parkinson's drugs. The trial plans to enroll about 60 people aged 50 to 70 with Parkinson's diagnosed using the UPDRS who are on conventional treatment. People who are pregnant or breastfeeding, have significant liver or kidney problems, current use of other anti-inflammatory drugs, substance abuse, or known allergy to the medications are excluded.
Locations
- Mansoura University, Al Mansurah, Egypt
Frequently Asked Questions
- What is this trial testing?
- This trial is studying L-dopa. Researchers are testing whether adding etoricoxib, a selective COX-2 anti-inflammatory, to usual levodopa care is safe and may help by reducing the inflammation that might contribute to neuron damage and symptom worsening in Parkinson's. Etoricoxib works by blocking the COX-2 enzyme and lowering prostaglandin-driven inflammation; it does not boost dopamine like levodopa, but by reducing inflammatory stress it could protect neurons or slow decline, and the study will watch for safety and interactions with standard Parkinson's drugs. The trial plans to enroll about 60 people aged 50 to 70 with Parkinson's diagnosed using the UPDRS who are on conventional treatment. People who are pregnant or breastfeeding, have significant liver or kidney problems, current use of other anti-inflammatory drugs, substance abuse, or known allergy to the medications are excluded.
- Who can participate?
- Participants must be between 50 Years and 70 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This Phase 2 trial is estimated to last approximately 1 year and 9 months.